Table 2

Selected clinical trials for using TIL-based adoptive T-cell therapy

StrategyClinicalTrials.gov identifierTumour typeSettingPhaseTreatmentTarget accrual
TIL-based adoptive T-cell therapyNCT04072263Ovarian cancerAdvancedPhase 1, Phase 2TILs, interferon alfa 2A, carboplatin, paclitaxel12
NCT03992326Solid tumourAdvancedPhase 1TILs, cyclophosphamide, fludarabine, IL-2, radiotherapy60
NCT03412526Ovarian cancerAdvancedPhase 2Fludarabine, radiation, TIL administration, IL-215
TIL-based adoptive T-cell therapy with checkpoint inhibitorsNCT03296137CancerAdvancedPhase 1/2Autologous TILs, ipilimumab, nivolumab, IL-2, cyclophosphamide, fludarabine25
NCT03158935Ovarian cancer, melanomaAdvancedPhase 1Cyclophosphamide, fludarabine, pembrolizumab, TILs, IL-224
NCT02652455MelanomaAdvancedEarly Phase 1Nivolumab, surgery to remove tumour for growth of TIL, CD137
cyclophosphamide, fludarabine, TIL Infusion, IL-2
11
NCT03935347UrothelialAdvancedPhase 2Cyclophosphamide, fludarabine, pembrolizumab, autologous TILs, LN-145, IL-212
NCT02621021MelanomaAdvancedPhase 2Cyclophosphamide, fludarabine, IL-2, pembrolizumab, young TIL170
NCT03645928Melanoma, head and neck, lung cancerAdvancedPhase 2Lifileucel, LN-145, pembrolizumab48
Clonal neoantigen adoptive T-cell therapyNCT04032847Lung cancerAdvancedPhase I/IIaATL001, autologous clonal neoantigen T- cells50
NCT03997474MelanomaAdvancedPhase I/IIaATL001, autologous clonal neoantigen T-cells20
  • IL-2, interleukin-2; TILs, tumour infiltrating lymphocytes.